Topical Loteprednol Pretreatment Reduces Cyclosporine Stinging in Chronic Dry Eye Disease

Published on Feb 19, 2011in Journal of Ocular Pharmacology and Therapeutics1.925
· DOI :10.1089/JOP.2010.0085
John D. Sheppard21
Estimated H-index: 21
(EVMS: Eastern Virginia Medical School),
Stephen V. Scoper3
Estimated H-index: 3
,
Sandeep S. Samudre7
Estimated H-index: 7
Sources
Abstract
Abstract Purpose: This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication tolerability between those patients who receive topical corticosteroids prior to initiation of topical cyclosporine 0.5% emulsion (tCSA) therapy for chronic dry eye disease (CDED) and those who received tCSA and were not first induced with corticosteroid drops. tCSA is the only approved medication for CDED. Stinging is the most common side effect of tCSA and reason for tCSA discontinuation. This analysis describes an effective pharmacologic means to reduce tCSA stinging and subsequent discontinuation. Methods: Thirty-six consecutive patients were initially treated with loteprednol etabonate (LE) 0.5% (Lotemax; Bausch & Lomb) for a period ranging from 2 to 16 months prior to institution of concomitant tCSA (Restasis™; Allergan). Clinical parameters (fluorescein staining, conjunctival redness, tear meniscus) were compared over a period of 6 months to a second cohort of 36 c...
📖 Papers frequently viewed together
4 Authors (Kenneth Sall, ..., Brenda L. Reis)
676 Citations
161 Citations
12 Authors (Michael A. Lemp, ..., Ikuko Toda)
2,210 Citations
References16
Newest
#1Mohammad Ali Javadi (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 32
#2Sepehr Feizi (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 19
Our understanding of keratoconjunctivitis sicca (KCS), also known as dry eye syndrome, has been changed over recent years. Until lately, the condition was thought to be merely due to aqueous tear insufficiency. Today, it is understood that KCS is a multifactorial disorder due to inflammation of the ocular surface and lacrimal gland, neurotrophic deficiency and meibomian gland dysfunction. This change in paradigm has led to the development of new and more effective medications.
95 Citations
#1Edward J. HollandH-Index: 54
#2Ali R. DjalilianH-Index: 27
Last. Jeffrey P SandersonH-Index: 1
view all 3 authors...
PURPOSE: To describe a clinically observed reduction in intraocular pressure (IOP) without increased allograft rejection in known "steroid responders" using loteprednol etabonate 0.5% ophthalmic suspension as second-line rescue therapy after corneal transplantation. METHODS: Medical records from a prespecified 15-month period were retrospectively reviewed for all post-corneal transplant patients in whom loteprednol etabonate was initiated and prednisolone acetate 1.0% ophthalmic suspension withd...
31 CitationsSource
Ocular inflammatory diseases impose a significant medical and economic burden on society. Corticosteroids are potent anti-inflammatory agents that have been used successfully to treat ocular inflammation. Topical corticosteroids provide maximal drug delivery, and are used to reduce the signs and symptoms of intraocular and ocular surface inflammation. However, side effects associated with topical corticosteroids—including increased intraocular pressure, risk of cataract formation after long-term...
61 CitationsSource
#1Michael A. LempH-Index: 52
#2Christophe BaudouinH-Index: 80
Last. Ikuko TodaH-Index: 40
view all 12 authors...
2,210 CitationsSource
#1Ashley Behrens (Johns Hopkins University)H-Index: 23
#2John Doyle (Analytica)H-Index: 50
Last. Samuel C. YiuH-Index: 1
view all 22 authors...
Purpose: To develop current treatment recommendations for dry eye disease from consensus of expert advice. Methods: Of 25 preselected international specialists on dry eye, 17 agreed to participate in a modified, 2-round Delphi panel approach. Based on available literature and standards of care, a survey was presented to each panelist. A two-thirds majority was used for consensus building from responses obtained. Treatment algorithms were created. Treatment recommendations for different types and...
406 CitationsSource
#1David A. Berntsen (OSU: Ohio State University)H-Index: 18
#2G.L. Mitchell (OSU: Ohio State University)H-Index: 10
Last. Jason J. Nichols (OSU: Ohio State University)H-Index: 57
view all 3 authors...
Purpose: To assess the reliability of a lissamine green grading scale for conjunctival images. Methods: A 20-second video clip of the right eye of 288 contact lens-wearing individuals was recorded using a digital slip-lamp camera after instilling liquid lissamine green. A single nasal and temporal still image were selected. A masked reader used the Oxford grading scale to grade the images on two occasions whereas a second masked reader graded each image on 1 occasion. K statistics and 95% confid...
27 CitationsSource
15 CitationsSource
This study objectively compares efficacy of dexamethasone Na phosphate 0.1%, fluorometholone 0.1% (FML), loteprednol etabonate 0.5% (Lotemax™ [LE]; Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL), prednisolone acetate 1% (Pred Forte® [PRED F]; Allergan Pharmaceuticals, Irvine, CA), and generic prednisolone acetate 1% (PRED A). These steroids were administered for 24 hours or 72 hours to New Zealand white rabbits with endotoxin-induced uveitis. Intraocular pressure (IOP), slit-lamp examination, a...
41 CitationsSource
#1Haroon Ilyas (USF: University of South Florida)H-Index: 1
#2Charles B. SlonimH-Index: 9
Last. Melvin SchulmanH-Index: 1
view all 5 authors...
PURPOSE: To determine the long-term safety of the topical steroid, loteprednol etabonate 0.2%, in the treatment of seasonal and perennial allergic conjunctivitis. METHODS: A retrospective review of 397 patients from three private ophthalmologic practices treating seasonal and perennial allergic conjunctivitis with long-term loteprednol etabonate 0.2% was performed. Chart review of slitlamp findings and intraocular pressure measurements during follow-up visits was performed to determine the incid...
58 CitationsSource
#1Anthony J. Bron (University of Oxford)H-Index: 62
#2Victoria EvansH-Index: 8
Last. Janine A. SmithH-Index: 28
view all 3 authors...
AbstractPurposeTo describe the Oxford Scheme for grading ocular surface staining in dry eye and to discuss optimization of stain detection using various dyes and filters. Also, to propose a sequence of testing for dry eye diagnosis.MethodsThe grading of corneal and conjunctival staining is described
780 CitationsSource
Cited By45
Newest
Commercial topical ocular formulations for hydrophobic actives rely on the use of suspensions or oil in water emulsions and neither of these formulation modalities adequately promote drug penetration into ocular tissues. Using the ocular relevant hydrophobic drug, cyclosporine A (CsA), a non-irritant ocular penetration enhancer is showcased, which may be used for the formulation of hydrophobic actives. The activity of this penetration enhancer is demonstrated in a healthy rabbit model. The Molec...
Source
The purpose is to perform a cost effectiveness analysis amniotic membrane vs. topical medications in the use of treating dry eye disease. A cost effectiveness analysis comparing amniotic membrane + other topical medications to topical cyclosporine A + other topical medications was evaluated using accepted decision tree modeling software. TreeAge Pro 2019 software was used to evaluate the base case costs over a one year timeframe. Sensitivity analysis was performed on those variables which had th...
2 CitationsSource
Source
#1Kenneth A Beckman (OSU: Ohio State University)H-Index: 6
#2James KatzH-Index: 1
Last. Audrey Talley RostovH-Index: 1
view all 4 authors...
Dry eye disease (DED) is a common ocular condition that can impair vision and may adversely impact quality of life. Due to the inflammatory nature of this disorder, topical corticosteroids are an effective treatment option, particularly for moderate-to-severe DED when first-line treatments, such as ocular lubricants, are insufficient. Loteprednol etabonate (LE) is a retrometabolically designed corticosteroid with a low propensity to cause corticosteroid-related adverse effects, such as elevated ...
1 CitationsSource
#1Min-Ji Kang (Catholic University of Korea)H-Index: 1
#2Youn-Hee Kim (Catholic University of Korea)H-Index: 1
Last. So-Hyang Chung (Catholic University of Korea)H-Index: 12
view all 7 authors...
ABSTRACTPurpose: To evaluate the efficacy and safety of a novel topical cyclosporin A 0.05% nanoemulsion in comparison with a conventional emulsion in primary Sjogren’s syndrome dry eyes.Methods: P...
5 CitationsSource
#1Saama Sabeti (Harvard University)H-Index: 2
#2Ahmad Kheirkhah (University of Texas Health Science Center at San Antonio)H-Index: 25
Last. Reza Dana (MEE: Massachusetts Eye and Ear Infirmary)H-Index: 86
view all 4 authors...
Abstract Meibomian gland dysfunction (MGD) is the leading cause of evaporative dry eye disease and is one of the most common conditions encountered by eye care providers. MGD is characterized by obstruction of the meibomian gland terminal ducts and/or changes in their glandular secretion, resulting in changes in tear film stability, inflammation, and symptoms of irritation. There is no gold standard treatment for MGD, but rather a diversity of options. Conservative measures include warm compress...
18 CitationsSource
#1Jae Yeong Park (PNU: Pusan National University)H-Index: 2
#2Sang Cheol Yang (PNU: Pusan National University)H-Index: 3
Last. Jong Soo Lee (PNU: Pusan National University)H-Index: 17
view all 6 authors...
1 CitationsSource
: Dry eye disease (DED) is a multifactorial disease of ocular surface and tear film, and is a common disorder treated by eye care providers. It is well established that ocular surface inflammation has an important role in the pathophysiology of DED and that anti-inflammatory cyclosporine A (CsA) improves the treatment outcomes of most patients with DED. The purpose of this review is to provide guidance for practitioners in the use of topical CsA for the management of DED to improve patient satis...
6 CitationsSource
#1Terry Kim (Duke University)H-Index: 32
#2Kenneth Sall (Research Medical Center)H-Index: 15
Last. Preeya K. Gupta (Duke University)H-Index: 17
view all 6 authors...
Purpose: KPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract surgery. Materials and methods: In two multicenter, randomized, double-masked, parallel-group, vehicle-controlled clinical trials, 386 participants with ≥ grade 2 anterior chamber cells (≥6 cells) on ...
11 CitationsSource
#1Hui Lin (Johns Hopkins University)H-Index: 9
#2Ying Liu (Johns Hopkins University)H-Index: 3
Last. Samuel C. Yiu (Johns Hopkins University)H-Index: 1
view all 6 authors...
Abstract Purpose To investigate the efficacy of a single subconjunctival injection of dendrimer-dexamethasone conjugate in a rabbit model of induced autoimmune dacryoadenitis (AID). Methods Dendrimer biodistribution after subconjunctival injection in AID animals was evaluated using Cy5-labelled dendrimer (D-Cy5) and confocal microscopy. Diseased animals were treated with free dexamethasone (Free-Dex), dendrimer-dexamethasone (D-Dex), or saline via a single subconjunctival injection. The efficacy...
13 CitationsSource